Le Lézard
Classified in: Health
Subjects: CCA, BFA, FVT

Precision Optics to Present at Lytham Partners Virtual Investor Conference


GARDNER, Mass., Oct. 6, 2020 /PRNewswire/ -- Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, is scheduled to participate in a virtual presentation and fireside chat at the October 2020 Lytham Partners Virtual Investor Conference on Wednesday, October 7, 2020 at 2:00pm ET (11:00am PT).

A webcast of the presentation will be posted under the investor relations section of Precision Optics' website at www.poci.com or can be accessed at https://www.webcaster4.com/Webcast/Page/2109/37787. A replay of the presentation will be available following the event.

Management will also be participating in virtual one-on-one meetings. To arrange a meeting, please contact Robert Blum of Lytham Partners at [email protected] or visit www.lythampartners.com/virtual.

About Precision Optics Corporation
Precision Optics Corporation enables innovation in minimally invasive surgery, diagnostics and treatment through optics and photonics. Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, Microprecisiontm micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for market-leading medical device companies. The Company's innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures. The Company's website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.

About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by the Company's management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company's annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law. 

Company Contact:
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Phoenix | New York
Telephone: 602-889-9700
[email protected]

SOURCE Precision Optics Corporation


These press releases may also interest you

at 07:45
IntelGenx Technologies Corp. (the "Company" or "IntelGenx") announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the "Annual Meeting"), shareholders voted in favour of all items of business put forth by the...

at 07:30
Carisma Therapeutics Inc.  ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using...

at 07:30
NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer's Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of...

at 07:30
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has...

at 07:30
? Announces Significant Refinancing Transactions and Amends Royalty Agreement with HealthCare Royalty Extending Vast Majority of Its Debt Maturities into 2028 and 2029, Well Beyond Expected Data Readouts and Potential Approvals from the Company's...

at 07:28
Naborforce, an age-tech company whose platform provides on-demand everyday assistance to seniors, today announced that it has expanded its nationally renowned services to Greensboro, Winston-Salem, High Point, and the Greater Wilmington Region. The...



News published on and distributed by: